First-line PD-1/VEGF bispecific antibody plus chemotherapy in triple-negative breast cancer: a phase 2 trial
Nature Medicine, Published online: 12 August 2026; doi:10.1038/s41591-026-04564-7 In a multicenter, phase 2 trial, patients with treatment-naive locally advanced unresectable or metastatic triple-negative breast cancer were treated with the PD-1/vascular endothelial growth factor bispecific antibody ivonescimab plus chemotherapy, resulting in encouraging preliminary objective response rates,…
We haven't written up this one. Nature Medicine has the full story — the link below goes straight to it.
